Evidence map›Paper›PMID 40867279›Full record

ReviewCancers2025

Endocrine Adverse Events Induced by Cancer Treatments: The Role of

Luca Giovanella, Murat Tuncel, Alfredo Campennì, Rosaria Maddalena Ruggeri, Martin Huellner, Petra Petranović Ovčariček

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luca GiovanellaDepartment of Nuclear Medicine and Thyroid Diseases, Gruppo Ospedaliero Moncucco, 6900 Lugano, Switzerland.
Murat TuncelDepartment of Nuclear Medicine, Hacettepe University, 06100 Ankara, Turkey.ORCID 0000-0003-2352-3587
Alfredo CampennìUnit of Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98124 Messina, Italy.ORCID 0000-0002-0177-939X
Rosaria Maddalena RuggeriUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.ORCID 0000-0001-8899-684X
Martin HuellnerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-4849-3292
Petra Petranović OvčaričekDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10000 Zagreb, Croatia.ORCID 0000-0003-1946-2128

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have revolutionized cancer therapy, substantially improving survival across a broad range of malignancies. However, these agents are associated with a unique profile of endocrine immune-related adverse events (irAEs), including thyroiditis, hypophysitis, adrenalitis, and pancreatitis, which differ significantly from the toxicities seen with conventional chemotherapy. These complications often arise unpredictably during treatment and may result in irreversible hormone deficiencies requiring lifelong replacement, underscoring the importance of early detection.

Indexed as

adrenalitiscancer immunotherapyendocrine toxicityFDGhypophysitisimmune-related adverse eventsmetabolic imagingpancreatitisPET/CT imagingprecision oncologythyroiditis

Identifiers

PMID40867279
PMCPMC12384139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.